HS and AFM performed the NMR studies and assisted in data analysis. MAA assisted in the conception of the study and contributed to data analysis and manuscript editing. All authors

read and approved the final manuscript.”
“Background Candida albicans is a commensal of human microflora, residing at the oral cavity, AG-881 cost the gastrointestinal tract, the vaginal and the urinary environments, that acts as an opportunistic pathogen [click here reviewed by 1]. C. albicans commonly causes infections such as denture stomatitis, thrush, and urinary tract-infections, but can also provoke more severe systemic infections. These are frequently life-threatening, in particular in immuno-compromised individuals, whose numbers are constantly increasing due to organ transplant, chemotherapy, or, more importantly, to the prevalence of AIDS and Hepatitis C [reviewed by [1]]. Given the limited number of suitable and effective antifungal drugs, together with increasing drug resistance of the pathogens, it is important that research community addresses, and ultimately discloses, the

following yet unsolved questions: a) how the transformation from commensal to pathogen takes place, b) how it can be prevented, c) which are the mechanisms underlying antifungal drugs resistance. All of these culminate in the need to search for new and better agents that target fundamental biological processes and/or SB525334 ic50 pathogenic determinants. C. albicans, as most pathogens, has developed Vildagliptin an effective

battery of virulence factors and specific strategies to assist the ability to colonize host tissues, cause disease, and overcome host defences [reviewed by [2]]. An outstanding attribute of C. albicans biology is its capacity to grow in a diversity of morphological forms, ranging from unicellular budding yeast (blastospores), pseudohyphae, to true hyphae with parallel-sided walls [3–5]. The yeast-hyphae transition contributes to tissue invasion and to the escape from phagocyte cells after host internalization [6], and is therefore considered an important virulence factor [4, 5, 8–11]. Additionally, several other factors have been described in association with virulence, including the production of proteins that mediate adherence, the colonization and invasion of host tissues, the maintenance of cell wall integrity, phenotypic switching, and the avoidance of the host immune response [12–18]. Many of these virulence factors are glycosylphosphatidylinositol (GPI) – anchored proteins, which comprise 88% of all covalently linked cell wall proteins in C. albicans [14], many of which associated with the lipid-ordered domains. In spite of all these knowledge, we are still far from fully understanding the precise mechanism(s) driven by Candida switch from commensal to pathogen status.

21 26.85 0.000 4.334 34.422 Hsp90-beta mRNA positive / negative 16.25 10.08 0.002 2.462 107.24 selleck Annexin A1 positive / negative 6.6 15.09 0.000 2.415 18.04 Annexin A1 mRNA positive / negative 13.33 9.11 0.003 2.169 81.95 The expression levels of Hsp90-beta and annexin A1 increased in the cultured human lung cancer cells We examined the cultured human lung

cancer cell lines for the expressions of Hsp90-beta and annexin A1. We compared these levels to those obtained from cultured cells derived from normal lung tissues. For the control cells, we used 16 HBE cell lines, which originated from the normal human bronchial epithelium. The Hsp90-beta and annexin A1 protein levels exhibited significantly upregulated expression in the A549, H520, and H446 cell lines compared with the 16 HBE cell lines. Meanwhile, a weak difference in expression was observed among the A549, H520, and H446 cell lines, which revealed that the Hsp90-beta and annexin A1 protein levels were slightly higher in the H446 and A549 cell lines compared with others, but the results was not statistically significant (Figure 6). Figure 6 Protein expression of Hsp90-beta and annexin A1 in cell lines using Western blot analysis. Varied expression levels of Hsp90-beta and annexin A1 in cell levels selleckchem were noted, but was generally upregulated in most lung cancer cell lines (except the H520) compared with the 16 HBE cell lines. Discussion In this Clomifene study, quantitative

proteomic analysis was performed to identify the candidate upregulated proteins in lung cancer. Twenty-six different gene products were successfully identified as differentially expressed proteins between the lung cancer and the

normal bronchial epithelial cell lines. The differential proteins are involved in various biological processes such as skeletal development, protein binding, calcium ion binding, cell motility, signal transduction, cell growth, cell-cell signaling, and glycolysis, which are all associated with cancer development and progression. Among these processes, Hsp90-beta and annexin A1 were remarkably upregulated in the lung cancer cell lines. The overexpression of Hsp90, which is the classic chaperone family in cancer, has been related to the prognosis and evolution of neoplasia similar to other Hsps. Hsp90 has two main isoforms, namely, Hsp90-alpha and Hsp90-beta. A study of various tumor cell lines revealed that Hsp90-beta was expressed in HCT116 and HeLa cells. In addition, Hsp90-beta was found in Saos-2 (osteosarcoma), SK-N-SH, HL-60 (acute promyelocytic leukemia), and A375 (malignant melanoma) cell lines [13]. Annexins are calcium and phospholipid-binding proteins that form an evolutionarily conserved multigene family, and the members of its family are widely expressed in mammals. The this website dysregulation of the annexin family members including annexin A1, A2, A5, A6, A7, A8, and A9, among others, were reported in numerous cancers.

Cornel Els Dequeker Simon Dyson Charlotte Eddy Jon Emery Sultana M.H. Faradz Philip Giampietro Piero Giordano Roberto Giugliani Anna Gluba Leslie J. Greenberg Lidewij Henneman Shirley Hodgson Jürgen Horst Claude Houdayer Wendy Koster Amanda Trichostatin A research buy Krause Michael

Krawczak Ulf Kristoffersson Nina Larsson Patrick Linsel-Nitschke E.C. Mariman Sarabjit Mastana Carole McKeown Sylvia Ann Metcalfe Barend Middelkoop Anna Ku-0059436 purchase Middleton Konstantin Miller Bernadette Modell Irmgard Nippert Peter R. Nippert Håkan Olsson Nicholas Pachter Christine Patch Victor Penchaszadeh Martin Richards Joerg Schmidtke Udo Seedorf Jorge Sequeiros Maria Soller Leo P. ten Kate Ron Trent Xiangmin Xu Ron Zimmern”
“In his letter, Dr Zimmern seeks to dispel the notion that community genetics is unique and different from public health genomics, Selleck Fedratinib and he argues instead that both fields are “in essence one single discipline”. Let me, first of all, clarify that a comparison of both fields was not the primary aim of my commentary. My commentary is first of all based on a detailed study of the contents of the former journal

Community Genetics. The aim of this study was a deeper understanding of the way in which the proponents of this field have defined their ambitions and agenda; however, the years in which the volumes of Community Genetics were published was also the time in which public health genomics began to emerge as a new field. So, I also became interested in attempts

isometheptene of the proponents of community genetics to define the “uniqueness” of their own endeavour “in the light of” public health genomics. In doing so, I further added my own reflections on this new and emerging field. As I have observed in my commentary, community genetics and public health genomics are moving from different starting points but nevertheless are heading, in several respects, to a similar approach. Indeed, given my own observations on this point, I can agree with most of what Dr. Zimmern has to say about the close relation between the two fields; however, even though both fields have many elements in common, they do not simply coincide in terms of their agenda and ambitions. This also becomes clear from Dr. Zimmern’s own perception of community genetics as a “subset” of public health genomics. We find, in one of the editorials in the journal Community Genetics, a similar distinction in terms of the extension of both fields. Ironically, in this case, ten Kate conversely defines public health genomics as a nuclear family “within the extended family of community genetics” (ten Kate 2000). More important of course than these different and conflicting demarcations, are the different starting points from which both fields are approaching each other. The different roots of community genetics and public health genomics remain of crucial importance for our understanding of the particular focus defining each field.

All other isolates were found susceptible to these Temsirolimus cell line two antimicrobial agents (Table 4). Table 4 Results of antimicrobial susceptibility testing of Cronobacter isolates. Isolate S S3 AMP W CN SH FR N CFS-FSMP 1500 15.70

18.30 19.94 23.78 19.20 16.99 19.60 6.29* CFS-FSMP 1501 17.56 28.72 25.21 29.26 21.47 22.16 21.83 17.97 CFS-FSMP 1502 16.54 28.72 20.30 22.98 21.28 22.37 21.30 17.75 CFS-FSMP 1503 18.67 24.94 23.36 25.80 23.17 22.53 23.14 18.95 CFS-FSMP 1504 17.86 30.42 21.97 24.31 22.12 23.05 22.68 17.92 CFS-FSMP 1505 18.33 29.49 22.40 26.27 21.79 24.27 22.73 19.03 CFS-FSMP 1506 18.74 31.27 22.24 25.45 23.09 23.27 23.36 19.31 CFS-FSMP 1507 17.91 30.37 22.80 25.38 21.71 28.50 23.30 18.88 CFS-FSMP 1508 17.95 32.25 22.89 27.49 20.81 21.05 23.21 17.85 CFS-FSMP 1509 18.27 23.43 22.74 26.38 21.55 22.36 22.55 17.89 CFS-FSMP 1510 17.51 26.33 22.95 7.02* 22.10 23.20 22.93 6.46* CFS-FSMP 1511

18.37 30.95 24.75 26.40 22.30 23.23 22.46 18.53 CFS-FSMP 1512 18.53 30.55 24.78 26.90 22.63 19.83 23.41 11.95* CFS-FSMP 1513 16.16 31.73 25.49 26.08 20.95 20.62 22.87 18.58 CFS-FSMP 1514 17.45 25.54 24.14 25.75 22.73 23.28 23.30 18.27 CFS-FSMP 1515 16.11 30.74 24.79 24.66 21.21 22.09 20.76 17.51 S mTOR kinase assay streptomycin, S3 MM-102 concentration compound Thalidomide sulphonamides, AMP ampicillin, W trimethoprim, CN gentamicin, SH spectinomycin, FR furazolidone, N neomycin; Green = susceptible, *Denotes resistance; diameter of inhibition zone was measured in mm. PFGE Analysis Macrorestriction of Cronobacter genomic DNA with XbaI yielded 10 to 17 DNA fragments ranging in size from 48.5 to 1,000 kbp. A dendrogram was compiled

which illustrates the fingerprint pattern similarities between the various Cronobacter isolates (Figure 2). In total, 8 pulse-types (denoted 1 through were identified that showed indistinguishable similarity. Figure 2 PFGE analysis showing the clustering of Cronobacter isolates recovered from dairy products. rep-PCR Analysis The rep-PCR typing yielded between 18 and 25 DNA fragments that ranged in size from 150 to 3,500 bp. A dendrogram representing the genetic relatedness amongst the isolates was composed (Figure 3). Amongst the collection, 3 rep-PCR cluster groups (denoted A, B and C) were identified that exhibited identical similarity. Figure 3 rep-PCR analysis illustrating the relatedness of Cronobacter isolates recovered from dairy products. recN Gene Sequencing The results of the recN sequence analysis determined that two Cronobacter species, C. sakazakii and C. malonaticus, had been isolated in this study.

persica 16-FTT0376a, 17-FTT0523a, 20-ISFtu2b and 28-pdpDb.  Amplifies only F. tularensis (only when including the probe). 16-FTT0376a and 17-FTT0523a  Amplifies F. tularensis subsp. mediasiatica, F. tularensis subsp.holarctica and 6/7 F. tularensis subsp. novicida. 28-pdpDb  Amplifies isolates from all clade 1 species as well as W. persica. 20-ISFtu2b Marker with missing sequences as well as mismatches in almost all subspecies represented. 21-ISFtu2a Navitoclax manufacturer Successful amplification was defined as having a primer score below two in both the forward

and reverse primers. a Have associated TaqMan probe which is not considered here. bDetection by variable-length amplicon which is not considered here. cScore of F.noatunensis subsp orientalis <2. Evaluation of sample-sequencing approaches for phylogenetic analyses In the phylogenetic comparison analysis, we focused not only on the entire Francisella genus, but also selleck chemicals llc analysed clades 1 and 2 separately. These sub-populations exhibit different lifestyles and environmental niches and are therefore of interest to different scientific fields [3, 7, 18]. The differences between the poorest and best resolved single marker topologies of the entire genus compared to the whole-genome reference topology (Figure 2) are highlighted in Figure 3A-C. All topologies are shown in Additional File 2. The parameter estimates of the phylogenetic

analysis are summarised in Additional File 3. In general for the analysis of the entire genus, the optimal substitution model was parameter rich, i.e. typically the generalised Thiamine-diphosphate kinase time-reversible (GTR) [31] or Hasegawa-Kishino-Yano (HKY85) [32] models with either invariant sites parameter (α) or rate heterogeneity over sites (Г). Moderate or even low parameter-rich substitution models were favoured in the separate clade analyses, in particular for clade 1, where Jukes-Cantor (JC) [33] or HKY85 models were found to be the optimal choice without α or Г. For clade 2, it was important to include the proportion of invariant sites parameter in the analyses, because of detected recombination events [3].

Figure 2 Whole-genome SNP phylogeny. The whole-genome phylogeny for 37 Francisella strains obtained with model averaging Alpelisib mouse implemented in jModelTest using PhyML software. The removed part of the branches connecting clade 1 and 2 covers a genetic distance of 0.03. Figure 3 Single-marker phylogenies. Single-marker phylogeny of the Francisella genus: (A) highest ranked marker 08-fabH, (B) lowest ranked marker 33-rpoB, and (C) whole-genome phylogeny. Rank is based on difference in resolution between alternative and whole-genome topology. Throughout the study, to facilitate the phylogeny comparisons, we made use of two metrics: degree of incongruence (inc) and difference in resolution (res). The two topologies compared were the reference topology, obtained from whole genome data, and the single-sequence or the concatenated marker sequences topology.

S. Gov’t).PubMedCentralPubMedCrossRef 31. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Wennersten C, Venkataraman L, Novick RP, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with

reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002;46(5):1492–502.PubMedCentralPubMedCrossRef 32. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field Ilomastat cost gel electrophoresis Caspase inhibitor typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41(11):5113–20.PubMedCentralPubMedCrossRef 33. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal

DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233–9.PubMedCentralPubMed 34. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3245–9.PubMedCentralPubMedCrossRef 35. Rose https://www.selleckchem.com/products/azd6738.html WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Verteporfin Chemother. 2008;52(3):831–6.PubMedCentralPubMedCrossRef 36. Ludwig F, Edwards B, Lawes T, Gould IM. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2012;50(10):3383–7.PubMedCentralPubMedCrossRef 37. Lee CH, Wang MC, Huang IW, Chen FJ, Lauderdale TL. Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant

Staphylococcus aureus during high-dose daptomycin treatment. Antimicrob Agents Chemother. 2010;54(9):4038–40.PubMedCentralPubMedCrossRef”
“Erratum to: Infect Dis Ther (2013) 2:27–36 DOI 10.1007/s40121-013-0006-6 The editors of Infectious Diseases and Therapy would like to make the following addition to the Acknowledgments section of the above-mentioned paper. This required wording was unintentionally missed off the original version of the manuscript. “Compliance with Ethics Guidelines: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

Ann Pharmacother 41:1792–1797PubMedCrossRef 39. Reinhard MJ, Hinkin CH, Barclay TR, Levine AJ, Marion S, Castellon SA, Longshore D, Newton T, Durvasula RS, Lam

MN, Myers H (2007) Discrepancies between self-report and objective measures for stimulant drug use in HIV: cognitive, medication adherence and psychological correlates. Addict Behav 32:2727–2736PubMedCrossRef 40. Jentzsch NS, Camargos PA, Colosimo EA, Bousquet J R406 (2009) Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy 64:1458–1462PubMedCrossRef 41. van de Steeg N, Sielk M, Pentzek M, Bakx C, Altiner A (2009) Drug-adherence questionnaires not valid for patients taking blood-pressure-lowering drugs in a primary health care setting. J Eval Clin Pract 15:468–472PubMedCrossRef 42. Chisholm MA, Lance CE, Williamson GM, Mulloy LL (2005) Development and validation check details of the immunosuppressant therapy adherence instrument (ITAS). Patient Educ Couns 59:13–20PubMedCrossRef 43. de Klerk E, van der Heijde D, van der Tempel H, van der Linden S (1999) Development of a

questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 26:2635–2641PubMed 44. Vandekerckhove M, Vermeire E, Weeren A, Van Royen P (2009) Validation of the Diabetes Obstacles Questionnaire (DOQ) to assess obstacles Nutlin-3 in living with type 2 diabetes in a Belgian population. Prim Care Diab 3:43–47CrossRef 45. Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka AM, Burns S, Nair K, Pathak A (2008) Patients’ adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 54:394–402PubMed 46. Foddy W (1993) Constructing questions for interviews and questionnaires: theory and practice in Pictilisib research buy social research. Cambridge University Press, CambridgeCrossRef”
“Introduction

In Sweden, the maternal age in both primi- and multipara mothers has steadily increased during the last three decades. In this period, the mean age of mothers giving birth, both primi- and multipara included, increased from 26.0 to 30.3 years of age. For primiparous women only, the age has increased from 23.8 to 28.4 years of age during the same period. In urban areas in Sweden, the age of mothers giving birth to their first born increased even more, from 24.8 years in 1973 to 30.1 years in 2005 [1]. It has been previously reported that advancing maternal age increases the risk of fetal death [2, 3], but also of other morbidities in the offspring, such as chromosome abnormalities and childhood cancers like leukemia and retinoblastoma [4, 5]. The maternal age has also been associated with the development of diabetes mellitus type 1 and schizophrenia in the offspring, but these associations were also found to be dependent on paternal age [6, 7].

J Microbiol Meth 2000, 2:175–179.CrossRef 48. Henriques M, Azeredo J, Oliveira R: Candida albicans and Candida dubliniensis : comparison of biofilm formation in terms of biomass and activity. Brit J Biomed Scien 2006, 63:5–11. 49. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J: Biofilms of non- Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009, selleck chemicals 20:1–9.CrossRef 50. Hiller E, Heine S, Brunner H, Rupp S: Candida albicans Sun41p, a putative glycosidase, is involved in morphogenesis, cell wall biogenesis, and biofilm formation. Eukaryot Cell 2007, 6:2056–2065.GDC-0068 concentration PubMedCrossRef 51. Nobile CJ, Mitchell AP: Genetics and genomics of Candida albicans

biofilm formation. Cell Microbiol 2006, 8:1382–1391.PubMedCrossRef 52. Selmecki A, Bergmann S, Berman J: Comparative genome hybridization reveals widespread aneuploidy in Candida albicans laboratory strains. Mol Microbiol 2005, 55:1553–1565.PubMedCrossRef 53. Brand A, MacCallum DM, Brown AJP, Gow NA, Odds FC: Ectopic expression of URA3 can infuence the virulence phenotypes and proteome of Candida albicans but can be overcome by targeted reintegration of URA3 at the RPS10 locus. Eukaryot Cell 2004, 3:900–909.PubMedCrossRef 54. Oelkers P, Tinkelenberg A, Erdeniz N, Cromley D, Billheimer J, Sturley S: A lecithin cholesterol acyltransferase-like gene mediates diacylglycerol esterification in yeast. J

Biol Chem 2000, 275:15609–15612.PubMedCrossRef 55. Silva L, Coutinho A, Fedorov A, Prieto M: Nystatin-induced lipid vesicles permeabilization see more is strongly dependent on sterol structure. Biochim Biophys Acta 2006, 1758:452–459.PubMedCrossRef 56. Klis FM, Selleck Staurosporine de Groot P, Hellingwerf

K: Molecular organization of the cell wall of Candida albicans . Med Mycol 2001, 39:1–8.PubMed 57. Klis FM, Mol P, Hellingwerf K, Brul S: Dynamics of cell wall structure in Saccharomyces cerevisiae . FEMS Microbiol Rev 2002, 26:239–253.PubMedCrossRef 58. Netea MG, Gow NA, Munro CA, Bates S, Collins C, Ferwerda G, Hobson RP, Bertram G, Hughes HB, Jansen T, Jacobs L, Buurman ET, Gijzen K, Williams DL, Torensma R, McKinnon A, MacCallum DM, Odds FC, van der Meer JW, Brown AJ, Kullberg BJ: Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006, 116:1642–1650.PubMedCrossRef 59. Angiolella L, Micoci MM, D’Alessio S, Girolamo A, Maras B, Cassone A: Identification of major glucan-associated cell wall proteins of C. albicans and their role in fluconazole resistance. Antimicrob Agents Chemother 2002, 1688–1694. 60. Herrero AB, Magnelli P, Mansour MK, Levitz SM, Bussey H, Abeijon C: KRE5 gene null mutant strains of Candida albicans are a virulent and have altered cell wall composition and hyphae formation properties. Eukaryot Cell 2004, 3:1423–1431.PubMedCrossRef 61.

, 2003). **mean of quantification by oprL qPCR tested in duplicate. NA: not applicable. P. aeruginosa BI 2536 manufacturer isolation Ten μl of liquefied sputum pure and diluted into 1/1000, were inoculated and incubated onto several non selective and selective media for P. aeruginosa isolation, including Columbia blood agar supplemented with 5% defribinated horse blood (Oxoid, Dardilly, France), Columbia chocolate agar (Oxoid), and cetrimide agar (Oxoid).

All media were incubated aerobically at 37°C for five days and monitored daily. All different morphotypes of bacterial colonies were identified phenotypically with conventional screening methods (Gram coloration, oxidase test) followed by mass spectrometry identification (MicroFlex LT, Bruker Daltonics, Germany) [33, 34]. Quantification was conducted based on the colony forming unit (CFU) counts and the dilution ratio of the plate. P. aeruginosa detection and quantification by quantitative PCR (qPCR) DNA extraction For each isolate of the bacterial EX527 collection, 1 ml of a 0.5 McFarland suspension was extracted. For each sputum sample, one of the two 1 ml-aliquots was treated by 5 min of sonication using a bath sonicator (Elamsonic

S10, Singen, Germany). After a 10 min-centrifugation (5000 g), the pellet was suspended in 200 μl of DNA free water. Ten μl of the IC2, an internal control provided in the DICO Extra r-gene™ kit (Argène, Verniolle, France), were added in each check details sample and, for each batch of extraction, in 200 μl of DNA free water as a negative control. DNA was extracted using the QIAamp DNA Minikit® (Qiagen, Courtaboeuf, France) according to the instructions of the manufacturer (“Tissue protocol”)

with elution volumes of 100 μl. oprL qPCR oprL qPCR was performed using primers OPRL-F and OPRL-R and hydrolysis probe ASK1 oprL-MGB, previously described by Joly et al. [30] (Table 2). The reaction mix comprised 12.5 μl of Qiagen Quantitect Probe Master Mix, 0.3 μM of each primer, 0.2 μM of hydrolysis probe and 4.5 μl of DNA extract, and was made up to a final reaction volume of 25 μl with water. A negative amplification control was used for each batch. For sputum samples, a standard curve provided a full concentration range of P. aeruginosa extending from 102 to 106 CFU/mL. Each qPCR assay was repeated twice, and the mean value of the quantification was calculated for each duplicate (Table 1). Cycling was performed on an ABI Prism 7300 Real Time PCR System (Applied Biosystem, Foster city, Californy), with an initial hold at 95°C for 15 min, followed by 50 cycles at 95°C for 15 s, and 60°C for 1 min. The oprL-MGB probe was labelled with carboxyfluorescein (FAM).

World J Surg 2004, 28:301–306.CrossRef 7. Wain J, Diep TS, Ho VA, Walsh AM, Hoa NTT, Parry CM: Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol 1998, 36:1683–1687. 8. Stewart PS, Costerton JW: Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358:135–138.CrossRef 9. Hetrick EM, Shin JH, Stasko NA, Johnson CB, Wespe DA, Holmuhamedov E, Schoenfisch MH: Bactericidal efficacy of

nitric oxide-releasing silica nanoparticles. ACS Nano 2008, 2:235–246.CrossRef 10. Diekema BV-6 DJ, Pfaller MA: Rapid detection of antibiotic-resistant organism carriage for infection prevention. Clin Infect Dis 2013, 56:1614–1620.CrossRef 11. Rai M, Yadav A, Gade A: Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009, 27:76–83.CrossRef 12. Lusby PE, Coombes AL, Wilkinson JM: Bactericidal activity of different GANT61 honeys against pathogenic bacteria. Arch Med Res 2005, 36:464–467.CrossRef 13. Liu X, Wong KKY: Application of Nanomedicine in Wound Healing. New York: Springer; 2013. 14. Berndt S, Wesarg F, Wiegand C, Kralisch D, Müller FA: Antimicrobial porous hybrids consisting of bacterial nanocellulose and silver nanoparticles. Cellulose 2013, 20:771–783.CrossRef 15. Nablo BJ, Rothrock AR, Schoenfisch MH: Nitric oxide-releasing

sol-gels as antibacterial coatings for orthopedic implants. Biomaterials 2005, 26:917–924.CrossRef 16. Li L-L, Wang H: Enzyme-coated mesoporous silica nanoparticles as efficient antibacterial agents in vivo. Adv Healthcare Mater 2013, 2:1351–1360.CrossRef 17. Witte M, Barbul A: Role of nitric oxide in wound repair. Am J Surg 2002, 183:406–412.CrossRef 18. Friedman A, Friedman J: New biomaterials for the sustained release of nitric oxide: past, present and future. Expert Opin Drug Deliv 2009, 6:1113–1122.CrossRef 19. Ghaffari A, Miller

CC, McMullin B, Ghaharya A: Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide 2006, 14:21–29.CrossRef 20. Marxer SM, Rothrock AR, Nablo BJ, Robbins ME, Schoenfisch MH: Preparation of nitric oxide (NO)-releasing sol - gels for BIX 1294 supplier biomaterial applications. Chem Mater 2003, 15:4193–4199.CrossRef 21. Carpenter AW, Slomberg DL, Rao KS, Schoenfisch MH: Influence CYTH4 of scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles. ACS Nano 2011, 5:7235–7244.CrossRef 22. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH: Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 2009, 30:2782–2789.CrossRef 23. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, Friedman JM: Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008, 19:12–20.CrossRef 24.